Cited by 1,102Cannabis and Cannabinoid ResearchForensic Toxicology and Drug AnalysisPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.

Human Cannabinoid Pharmacokinetics

Open access

Huestis, Marilyn A.·2007·Chemistry & Biodiversity

DOI 10.1002/cbdv.200790152PMC PMC2689518

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1002/cbdv.200790152

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,514
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
Russo, E. B., & Guy, G. W. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 608
Constituents of Cannabis sativa L. XVII. A review of the natural constituents
Turner, C. E., Elsohly, M. A., & Boeren, E. G. (1980) · Journal of Natural Products · doi:10.1021/np50008a001 · Cited by 599
Cannabis: pharmacology and toxicology in animals and humans
Adams, I. B., & Martin, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 576
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J., Brown, P., Pertwee, R., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 546

Flagged first, then by citations

Show all 173 references

Research works printed but not linked: 26

Agurell S., 1971, Acta Pharm. Suecica, 8, 391
Agurell S., 1986, Pharmacol. Rev., 38, 21
Azorlosa J. L., 1992, J. Pharmacol. Exper. Ther., 261, 114
Perez‐Reyes M., 1990, NIDA Res. Monograph, 99, 42
Harder S., 1997, Int. J. Clin. Pharmacol. Ther., 35, 155
Ohlsson A., 1981, NIDA Res. Monograph, 34, 250
Meier H. J., 1997, Schweiz. Med. Wochenschr., 127, 214
Brenneisen R., 1996, Int. J. Clin. Pharmacol. Ther., 34, 446
Vinciguerra V., 1988, N. Y. State J. Med., 88, 525
McArdle K., 2001, Toxicology, 168, 133
Garrett E. R., 1978, Adv. Biosci., 22, 105
Hunt C. A., 1980, J. Pharmacol. Exper. Ther., 215, 35
Lee C. C., 1985, NIDA Res. Monograph, 60, 110
Martin B. R., 1977, Res. Commun. Chem. Pathol. Pharmacol., 17, 457
Ben‐Zvi Z., 1974, Res. Commun. Chem. Pathol. Pharmacol., 8, 223
Harvey D. J., 1986, Rev. Biochem. Toxicol., 6, 221
Bornheim L. M., 1992, Drug Metab. Dispos., 20, 241
Halldin M. M., 1982, Drug Metab. Dispos., 10, 297
Chiang C. N., 1987, NIDA Res. Monograph
Bloom A. S., 1982, J. Pharmacol. Exper. Ther., 221, 97
Green M. D., 1997, Drug Metab. Dispos., 25, 1389
Mura P., 1999, Acta Clin. Belg., 1, 35
Soares J. R., 1982, NIDA Res. Monograph, 42, 44
Hawks R. L., 1982, NIDA Res. Monograph, 42, 125
Huestis M. A., 1992, Am. Acad. Forensic Sci. Annual Meeting, 190
Balabanova S., 1989, Beitr. Gerichtl. Med., 48, 45

Sorted by citations

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 604
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R. T., Harden, C. L., Greenwood, S. M., Morrison, G., Sommerville, K. W., On behalf of the GWPCARE1 Part A Study Group, et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005254 · Cited by 478
Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review
Svíženská, I. H., Dubový, P., & Šulcová, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 475
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
Stout, S. M., & Cimino, N. M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 350
Chemistry, metabolism, and toxicology of cannabis: clinical implications.
Sharma, P., Murthy, P., & Bharath, M. M. S. (2012) · Europe PMC (PubMed Central) · Cited by 338
Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J., Miyauchi, J. T., Tsirka, S. E., Ojima, I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618447 · Cited by 315
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 302
Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298
Medical Marijuana and Marijuana Legalization
Pacula, R., & Smart, R. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045128 · Cited by 254
Pharmacology of Medical Cannabis
Amin, M. R., & Ali, D. W. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21737-2_8 · Cited by 313
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup‐Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 320
Best Practice & Research Clinical Endocrinology & Metabolism
Grieb, M. (2009) · Cited by 276
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 277
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
Bruni, N., Pepa, C. D., Oliaro‐Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 317
Changing landscape of cannabis: novel products, formulations, and methods of administration
Spindle, T. R., Bonn‐Miller, M. O., & Vandrey, R. G. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.04.002 · Cited by 270
Cannabis use during pregnancy: Pharmacokinetics and effects on child development
Grant, K. S., Petroff, R., Isoherranen, N., Stella, N., & Burbacher, T. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.014 · Cited by 268
Cannabinoids: Therapeutic Use in Clinical Practice
Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., & Laezza, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063344 · Cited by 261
Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation
Rom, S., & Persidsky, Y. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9445-9 · Cited by 244
Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC
Hložek, T., Uttl, L., Kadeřábek, L., Balı́ková, M., Lhotková, E., Horsley, R. R., Nováková, P., Šíchová, K., Štefková, K., Tylš, F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.10.037 · Cited by 248
Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay
Cannaert, A., Storme, J., Franz, F., Auwärter, V., & Stove, C. P. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02600 · Cited by 223
A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain
Verrico, C., Wesson, S., Konduri, V., Hofferek, C., Vazquez-Perez, J., Blair, E., Dunner, K., Salimpour, P., Decker, W. K., & Halpert, M. (2020) · Pain · doi:10.1097/j.pain.0000000000001896 · Cited by 165
Towards Better Delivery of Cannabidiol (CBD)
Millar, S., Maguire, R., Yates, A. S., & O’Sullivan, S. E. (2020) · Pharmaceuticals · doi:10.3390/ph13090219 · Cited by 225
The Science of Marijuana
Iversen, L. L. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328240.001.0001 · Cited by 230
Pharmacology of cannabinoids in the treatment of epilepsy
Gaston, T. E., & Friedman, D. J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.016 · Cited by 222
Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …
Baron, E. P. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 219
Tasty THC: Promises and Challenges of Cannabis Edibles
RTI International, D., Barrus, D. G., Giombi, K., Cates, S. C., Gourdet, C., Peiper, N. C., Novak, S. P., Lefever, T. W., & Wiley, J. L. (2016) · doi:10.3768/rtipress.2016.op.0035.1611 · Cited by 198
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 210
Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk
Bertrand, K. A., Hanan, N., Honerkamp‐Smith, G., Best, B. M., & Chambers, C. (2018) · PEDIATRICS · doi:10.1542/peds.2018-1076 · Cited by 184
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process
Bhaskar, A., Bell, A., Boivin, M. R., Briques, W., Brown, M. R. D., Clarke, H. A., Cyr, C., Eisenberg, E., Silva, R. F. D. O., Frohlich, E., et al. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00073-1 · Cited by 191
Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
Nasrin, S., Watson, C. J. W., Pérez-Páramo, Y. X., & Lazarus, P. J. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000442 · Cited by 166
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia
Xiong, W., Cheng, K., Cui, T., Godlewski, G., Rice, K. C., Xu, Y., & Zhang, L. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.552 · Cited by 163
Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws
Bergamaschi, M. M., Karschner, E. L., Goodwin, R. S., Scheidweiler, K. B., Hirvonen, J., Queiróz, R. H. C., & Huestis, M. A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.195503 · Cited by 154
Self-citation
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 154
Simultaneous detection of salivary Δ9-tetrahydrocannabinol and alcohol using a Wearable Electrochemical Ring Sensor
Mishra, R. K., Sempionatto, J. R., Li, Z., Brown, C., Galdino, N. M., Shah, R., Liu, S., Hubble, L. J., Bagot, K. S., Tapert, S. F., et al. (2020) · Talanta · doi:10.1016/j.talanta.2020.120757 · Cited by 156
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
Brents, L. K., Gallus‐Zawada, A. E., Radominska-p, A., Vasiljevik, T., Prisinzano, T. E., Fantegrossi, W. E., Moran, J. H., & Prather, P. L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.004 · Cited by 143
Future Aspects for Cannabinoids in Breast Cancer Therapy
Kisková, T., Mungenast, F., Suváková, M., Jäger, W. R., & Thalhammer, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071673 · Cited by 143
The Impact of Marijuana on the Cardiovascular System: A Review of the Most Common Cardiovascular Events Associated with Marijuana Use
Latif, Z., & Garg, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061925 · Cited by 142
Deficits in striatal dopamine release in cannabis dependence
van de Giessen, E., Weinstein, J. J., Cassidy, C., Haney, M., Dong, Z., Ghazzaoui, R., Ojeil, N., Kegeles, L. S., Xu, X., Vadhan, N. P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.21 · Cited by 136
Sex differences and the endocannabinoid system in pain
Blanton, H. L., Barnes, R. C., McHann, M. C., Bilbrey, J. A., Wilkerson, J. L., & Guindon, J. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173107 · Cited by 151
Transfer of Inhaled Cannabis Into Human Breast Milk
Baker, T. E., Datta, P., Rewers‐Felkins, K., Thompson, H., Kallem, R. R., & Hale, T. W. (2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002575 · Cited by 141
Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer
Kis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148
Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation
Kopustinskienė, D. M., Masteiková, R., Lažauskas, R., & Bernatonienė, J. (2022) · Antioxidants · doi:10.3390/antiox11040660 · Cited by 155
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study
Brubacher, J. R., Chan, H., Erdelyi, S., Macdonald, S., Asbridge, M., Mann, R. E., Eppler, J., Lund, A., MacPherson, A. I., Martz, W., et al. (2019) · Addiction · doi:10.1111/add.14663 · Cited by 129
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues
Russo, E. B. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00309 · Cited by 128
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
Birnbaum, A. K., KARANAM, A. B., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M. J., Gramling-Aden, M. L., & Leppik, I. E. (2019) · Epilepsia · doi:10.1111/epi.16093 · Cited by 136
Cannabinoid-induced changes in respiration of brain mitochondria
Fišar, Z., Singh, N., & Hroudová, J. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.09.002 · Cited by 127
The therapeutic potential of cannabinoids for movement disorders
Kluger, B. M., Triolo, P. M., Jones, W. E., & Jankovic, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26142 · Cited by 123
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
Qian, Y., Gurley, B. J., & Markowitz, J. S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001089 · Cited by 123
Cannabinoids: Medical implications
Schrot, R. J., & Hubbard, J. R. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1145794 · Cited by 135
Chronic Adolescent Δ 9 -Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment
Murphy, M. N., Mills, S., Winstone, J., Leishman, E., Wager‐Miller, J., Bradshaw, H. B., & Mackie, K. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0034 · Cited by 131
The pharmacokinetics, efficacy, and safety of a novel selective‐dose cannabis inhaler in patients with chronic pain: A randomized, double‐blinded, placebo‐controlled trial
Almog, S., Aharon‐Peretz, J., Vulfsons, S., Ogintz, M., Abalia, H., Lupo, T., Hayon, Y., & Eisenberg, E. (2020) · European Journal of Pain · doi:10.1002/ejp.1605 · Cited by 123
Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint
Toennes, S. W., Ramaekers, J. G., Theunissen, E. L., Moeller, M. R., & Kauert, G. F. (2008) · Journal of Analytical Toxicology · doi:10.1093/jat/32.7.470 · Cited by 121
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-236 · Cited by 120
A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects
Knaub, K., Sartorius, T., Dharsono, T., Wacker, R., Wilhelm, M. G., & Schön, C. (2019) · Molecules · doi:10.3390/molecules24162967 · Cited by 119
Review of delta‐8‐tetrahydrocannabinol (Δ 8 ‐THC): Comparative pharmacology with Δ 9 ‐THC
Tagen, M., & Klumpers, L. E. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15865 · Cited by 125
Δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC, and 11-Nor-9-carboxy-THC Plasma Pharmacokinetics during and after Continuous High-Dose Oral THC
Schwilke, E. W., Schwope, D. M., Karschner, E. L., Lowe, R. H., Darwin, W. D., Kelly, D. L., Goodwin, R. S., Gorelick, D. A., & Huestis, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.122119 · Cited by 117
Self-citation
Cannabis and Cannabinoids for Chronic Pain
Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 115
Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration
Cherniakov, I., Izgelov, D., Barasch, D., Davidson, E. M., Domb, A. J., & Hoffman, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.011 · Cited by 111
The effects of cannabis and alcohol on driving performance and driver behaviour: a systematic review and meta‐analysis
Simmons, S. M., Caird, J. K., Sterzer, F. R., & Asbridge, M. (2022) · Addiction · doi:10.1111/add.15770 · Cited by 111
Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes
Lo, J. O.-T., Hedges, J. C., & Girardi, G. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.05.056 · Cited by 111
Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats
Freels, T. G., Baxter-Potter, L. N., Lugo, J. M., Glodosky, N. C., Wright, H. R., Baglot, S. L., Petrie, G. N., Yu, Z., Clowers, B. H., Cuttler, C., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2416-19.2020 · Cited by 105
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline
Braun, I. M., Bohlke, K., Abrams, D. I., Anderson, H., Balneaves, L. G., Bar-Sela, G., Bowles, D. W., Chai, P. R., Damani, A., Gupta, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02596 · Cited by 116
Cannabinoids in Parkinson's Disease
Bassi, M. S., Sancesario, A., Morace, R., Centonze, D., & Iezzi, E. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0002 · Cited by 114
Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study
Hausman‐Kedem, M., Menascu, S., & Kramer, U. (2018) · Brain and Development · doi:10.1016/j.braindev.2018.03.013 · Cited by 116
A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
Taylor, L., Crockett, J. C., Tayo, B., & Morrison, G. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1412 · Cited by 112
Communicating THC levels and ‘dose’ to consumers: Implications for product labelling and packaging of cannabis products in regulated markets
Hammond, D. G. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.07.004 · Cited by 106
Marijuana Use in Pregnancy: A Review
Thompson, R., DeJong, K. N., & Lo, J. O.-T. (2019) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000685 · Cited by 112
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Johal, H. S., Devji, T., Chang, Y., Simone, J. J., Vannabouathong, C., & Bhandari, M. (2020) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.1177/1179544120906461 · Cited by 105
ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
Shah, S., Schwenk, E. S., Sondekoppam, R. V., Clarke, H. A., Zakowski, M. I., Lynn, R. R., Yeung, B., Nicholson, K., Schwartz, G. S., Hooten, W. M., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2022-104013 · Cited by 113
An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine
Urits, I., Borchart, M. R., Hasegawa, M. E., Kochanski, J. J., Orhurhu, V., & Viswanath, O. (2019) · Pain and Therapy · doi:10.1007/s40122-019-0114-4 · Cited by 105
Use of cannabidiol (CBD) for the treatment of chronic pain
Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 111
Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Clauw, D. J., Goesling, J., & Williams, D. A. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.05.009 · Cited by 107
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry
Schwope, D. M., Scheidweiler, K. B., & Huestis, M. A. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5197-7 · Cited by 100
Self-citation
Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats
Baglot, S. L., Hume, C., Petrie, G. N., Aukema, R. J., Lightfoot, S. H. M., Grace, L. M., Zhou, R., Parker, L. A., Rho, J. M., Borgland, S. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03242-7 · Cited by 100
Scientific Opinion on the safety of hemp (Cannabis genus) for use as animal feed
(FEEDAP), E. P. O. A. A. P. O. S. U. I. A. F. (2011) · EFSA Journal · doi:10.2903/j.efsa.2011.2011 · Cited by 98
Cannabinoids in the Pathophysiology of Skin Inflammation
Scheau, C., Bădărău, I. A., Mihai, L.-G., Scheau, A.-E., Costache, D. O., Constantin, C., Călina, D. C., Căruntu, C., Costache, R. S., & Căruntu, A. (2020) · Molecules · doi:10.3390/molecules25030652 · Cited by 98
Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis
Schlienz, N. J., Spindle, T. R., Cone, E. J., Herrmann, E. S., Bigelow, G. E., Mitchell, J. M., Flegel, R. R., LoDico, C., & Vandrey, R. G. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107969 · Cited by 99
Effects of cannabis on cognitive function in patients with multiple sclerosis
Honarmand, K., Tierney, M. C., O'Connor, P. W., & Feinstein, A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212ab0c · Cited by 101
The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids
Cheung, K. A. K., Peiris, H. N., Wallace, G., Holland, O. J., & Mitchell, M. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236079 · Cited by 105
The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats
Izgelov, D., Shmoeli, E., Domb, A. J., & Hoffman, A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119201 · Cited by 103
Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin
(CONTAM), E. P. O. C. I. T. F. C. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4141 · Cited by 98
PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers
Atsmon, J., Cherniakov, I., Izgelov, D., Hoffman, A., Domb, A. J., Deutsch, L., Deutsch, F., Heffetz, D., & Sacks, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.12.020 · Cited by 97
Cannabis and Cannabinoids: Kinetics and Interactions
Foster, B. C., Abramovici, H., & Harris, C. S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.05.017 · Cited by 96
Cannabinoids as anticancer therapeutic agents
Kovalchuk, O., & Kovalchuk, I. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1742952 · Cited by 96
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders
Golub, V. M., & Reddy, D. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_7 · Cited by 106
Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450
Bansal, S., Maharao, N. V., Paine, M. F., & Unadkat, J. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000073 · Cited by 102
Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice
Torrens, A., Vozella, V., Huff, H., McNeil, B., Ahmed, F., Ghidini, A., Mahler, S. V., Huestis, M. A., Das, A., & Piomelli, D. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265892 · Cited by 88
Self-citation
Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study
Farokhnia, M., McDiarmid, G. R., Newmeyer, M. N., Munjal, V., Abulseoud, O. A., Huestis, M. A., & Leggio, L. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0756-3 · Cited by 94
Self-citation
Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
Matheson, J., & Foll, B. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.591979 · Cited by 85
Cannabis and Cannabis Edibles: A Review
Peng, H., & Shahidi, F. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c07472 · Cited by 92
Medical cannabis ‒ the Canadian perspective
Ramkellawan, S., Bober, S., Mindra, S., Moreau, J. M., & Ko, G. D. (2016) · Journal of Pain Research · doi:10.2147/jpr.s98182 · Cited by 91
Endocannabinoids: A Promising Impact for Traumatic Brain Injury
Schurman, L. D., & Lichtman, A. H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00069 · Cited by 95
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics
Cox, E. J., Maharao, N. V., Patilea-Vrana, G., Unadkat, J. D., Rettie, A. E., McCune, J. S., & Paine, M. F. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.001 · Cited by 91

Authors: Huestis, M. A.
Affiliations: National Institutes of Health (US)
Corresponding author: Huestis, Marilyn A.
ORCID: Huestis, Marilyn A.
Venue: Chemistry & Biodiversity
Publisher: Wiley
Published: 2007-08
Volume: 4
Issue: 8
Pages: 1770-1804
ISSN: 1612-1872 (ISSN-L)
1612-1880
DOI: 10.1002/cbdv.200790152
PMC: PMC2689518
OpenAlex: W2169754532
Cited by: 1,102
References: 173
Citations by year: 2026: 79 · 2025: 97 · 2024: 77 · 2023: 114 · 2022: 109 · 2021: 121 · 2020: 132 · 2019: 117 · 2018: 70 · 2017: 56 · 2016: 42 · 2015: 31 · 2014: 14 · 2013: 13 · 2012: 10
FWCI: 0.35
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 20 d)
Locations: Chemistry & Biodiversity (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute on Drug Abuse (Z01DA000413, Z01DA000415, Z01DA000412)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: cannabinoids, pharmacokinetics, human metabolism, drug absorption, distribution, metabolism, excretion
MeSH terms: Cannabinoids, Humans, Sweat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human Cannabinoid Pharmacokinetics

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks